Abstract
Background: In the last few decades, research into boron-containing compounds (BCCs) has notably increased in medicinal chemistry. Multiple maladies are now targeted by means of BCCs. Since bioinformatics tools have become a common and efficient methodology for drug design and materials science, their application to the study of BCCs is expected to intensify.
Objective: This review compiles the use of computational technology to elucidate the chemical-biological effects of BCCs, whether coming from natural sources or drug development strategies.
Results: A broad range of computational approaches facilitate pharmacochemical analysis of BCCs. The most focusing on the essential parameters of a boron atom, the reasons for an experimental event, and the shared pharmacodynamics, pharmacokinetics or toxic effects of components of a group of BCCs.
Conclusions: Some studies have examined the properties of the boron atom in molecules for designing drugs and biomaterials, others have been aimed to identify the best quantitative structure-activity relationship for a specific target, but lacking some experimental and theoretical data limit the use of boron in theoretical assays. A final remark is made as to the potential impact on BCC research that could result from advances in bioinformatics.
Keywords: Boron, organo-metallic, drug design, bioinformatics, computational chemistry, docking, molecular dynamics.
Graphical Abstract
Current Organic Chemistry
Title:Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Volume: 22 Issue: 3
Author(s): Erik Andrade-Jorge, Ana K. Garcia-Avila, Ana L. Ocampo-Nestor, Jose G. Trujillo-Ferrara and Marvin A. Soriano-Ursua*
Affiliation:
- Departamento de Fisiologia, Seccion de Estudios de Posgrado e Investigacion. Escuela Superior de Medicina, Instituto Politecnico Nacional. Plan de San Luis y Salvador Diaz Miron s/n, Casco de Santo Tomas, Mexico City 11340,Mexico
Keywords: Boron, organo-metallic, drug design, bioinformatics, computational chemistry, docking, molecular dynamics.
Abstract: Background: In the last few decades, research into boron-containing compounds (BCCs) has notably increased in medicinal chemistry. Multiple maladies are now targeted by means of BCCs. Since bioinformatics tools have become a common and efficient methodology for drug design and materials science, their application to the study of BCCs is expected to intensify.
Objective: This review compiles the use of computational technology to elucidate the chemical-biological effects of BCCs, whether coming from natural sources or drug development strategies.
Results: A broad range of computational approaches facilitate pharmacochemical analysis of BCCs. The most focusing on the essential parameters of a boron atom, the reasons for an experimental event, and the shared pharmacodynamics, pharmacokinetics or toxic effects of components of a group of BCCs.
Conclusions: Some studies have examined the properties of the boron atom in molecules for designing drugs and biomaterials, others have been aimed to identify the best quantitative structure-activity relationship for a specific target, but lacking some experimental and theoretical data limit the use of boron in theoretical assays. A final remark is made as to the potential impact on BCC research that could result from advances in bioinformatics.
Export Options
About this article
Cite this article as:
Andrade-Jorge Erik , Garcia-Avila K. Ana , Ocampo-Nestor L. Ana , Trujillo-Ferrara G. Jose and Soriano-Ursua A. Marvin *, Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds, Current Organic Chemistry 2018; 22 (3) . https://dx.doi.org/10.2174/1385272821666170427124336
DOI https://dx.doi.org/10.2174/1385272821666170427124336 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Current Medicinal Chemistry Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Inhibitors of Cholinesterases in Pharmacology: the Current Trends
Mini-Reviews in Medicinal Chemistry Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Current Pharmaceutical Design Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets